On October 6, 2015 MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, reported that data from the Company’s Phase II clinical studies of Pracinostat in elderly acute myeloid leukemia (AML) and previously untreated myelodysplastic syndrome (MDS) have been selected by the American Society of Hematology (ASH) (Free ASH Whitepaper) Program Committee for oral presentation at the 57th ASH (Free ASH Whitepaper) Annual Meeting & Exposition in Orlando on December 7, 2015 (Press release, MEI Pharma, OCT 6, 2015, View Source [SID:1234507652]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)
Abstract: 453
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Advances in Therapy
Presentation: Monday, December 7, 2015 at 7:30 am Eastern time

A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS)
Abstract: 911
Session: 637. Myelodysplastic Syndromes – Clinical Studies I
Presentation: Monday, December 7, 2015 at 7:15 pm Eastern time

Abstracts are expected to be available at www.hematology.org on Thursday, November 5, 2015 at 9:00 am Eastern time. In addition, the abstracts will be published online in the December 3, 2015 supplemental volume of Blood.